| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 75834-0144-05 | 75834-0144 | Temozolomide | Temozolomide | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Dec 7, 2021 | In Use | |
| 72578-0171-01 | 72578-0171 | Dexamethasone | Dexamethasone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Apr 15, 2024 | In Use | |
| 70518-3182-00 | 70518-3182 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Aug 5, 2021 | In Use | |
| 25021-0201-69 | 25021-0201 | Mesna | Mesna | 100.0 mg/mL | Ancillary Therapy | Chemoprotective | Detoxifying Agent | Intravenous | Apr 30, 2013 | Sep 13, 2019 | In Use |
| 00143-9555-01 | 00143-9555 | Leucovorin Calcium | Leucovorin Calcium | 50.0 mg/5mL | Ancillary Therapy | Chemoprotective | Antidote | Intramuscular, Intravenous | Sep 14, 1987 | In Use | |
| 00378-1940-01 | 00378-1940 | Lenalidomide | Lenalidomide | 25.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 6, 2022 | In Use | |
| 71872-7347-01 | 71872-7347 | Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 4.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intra-articular, Intralesional, Intramuscular, Intravenous, Soft Tissue | Apr 21, 2025 | In Use | |
| 72162-2418-00 | 72162-2418 | Raloxifene hydrochloride | Raloxifene hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Oct 31, 2024 | In Use | ||
| 72266-0126-01 | 72266-0126 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Feb 15, 2019 | In Use | |
| 72266-0152-01 | 72266-0152 | Zoledronic acid | Zoledronic acid | 5.0 mg/100mL | Ancillary Therapy | Bisphosphonate | Intravenous | Jun 12, 2023 | In Use | ||
| 76420-0376-01 | 76420-0376 | PREDNISONE | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jun 19, 2025 | In Use | |
| 70771-1152-00 | 70771-1152 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Dec 5, 2017 | In Use | |
| 59651-0300-90 | 59651-0300 | Tamoxifen Citrate | Tamoxifen Citrate | 20.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Aug 14, 2020 | In Use | ||
| 67296-0600-02 | 67296-0600 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Feb 12, 2003 | In Use | |
| 10544-0046-30 | 10544-0046 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jul 7, 2011 | In Use | |
| 00078-0180-01 | 00078-0180 | Octreotide Acetate | Sandostatin | 50.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Oct 21, 1988 | In Use | ||
| 63629-4413-01 | 63629-4413 | Tamoxifen Citrate | Tamoxifen Citrate | 20.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Mar 7, 2011 | In Use | ||
| 00078-0182-01 | 00078-0182 | Octreotide Acetate | Sandostatin | 500.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Oct 21, 1988 | In Use | ||
| 00002-1717-28 | 00002-1717 | Imlunestrant | Inluriyo | 200.0 mg/1 | Hormonal Therapy | Estrogen Receptor Antagonist | ER⍺ | Oral | Oct 16, 2025 | In Use | |
| 00703-0031-01 | 00703-0031 | Methylprednisolone Acetate | Methylprednisolone Acetate | 40.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intra-articular, Intralesional, Intramuscular, Soft Tissue | Mar 8, 2005 | In Use | |
| 00245-0824-30 | 00245-0824 | Everolimus | TORPENZ | 7.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jun 24, 2024 | In Use | |
| 72064-0120-30 | 72064-0120 | avapritinib | Ayvakit | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | PDGFR, KIT, CSFR1 | Oral | Jan 9, 2020 | In Use | |
| 72603-0346-01 | 72603-0346 | Doxorubicin Hydrochloride | Doxorubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Aug 1, 2025 | In Use | |
| 72606-0559-02 | 72606-0559 | Busulfan | Busulfan | 6.0 mg/mL | Chemotherapy | Alkylating Agent | Alkylsulfonate | Intravenous | Dec 1, 2019 | In Use | |
| 43598-0683-25 | 43598-0683 | Doxorubicin Hydrochloride | Doxorubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Mar 13, 2018 | In Use |
Found 12250 results — Export these results
Home